Benchmarking the In Vitro Activities of Moxifloxacin and Comparator Agents against Recent Respiratory Isolates from 377 Medical Centers throughout the United States

To benchmark the activity of moxifloxacin (a newer fluoroquinolone), a U.S. study comprising 16,141 contemporary isolates ofStreptococcus pneumoniae (5,640),Haemophilus influenzae (6,583), andMoraxella catarrhalis (3,648) referred from 377 institutions during 1998 is described. ForS. pneumoniae the modal MIC and MIC at which 90% of the isolates were inhibited (MIC90 ) for moxifloxacin were 0.12 and 0.25 μg/ml, respectively, independent of susceptibility to other drug classes, geography, or site of infection. Eleven isolates were intermediate or resistant to levofloxacin and grepafloxacin; of these isolates, 1 remained susceptible to sparfloxacin, 2 remained susceptible to moxifloxacin, and 4 remained susceptible to trovafloxacin. All 11 isolates possessed classic mutations ingyrA and/orparC known to confer reduced susceptibility to fluoroquinolones. Four isolates (originating from four separate states) belonging to a multidrug-resistant, fluoroquinolone-resistant clone were identified by pulsed-field gel electrophoresis. For moxifloxacin and trovafloxacin, at least 87% of isolates demonstrated MICs ≥3 twofold concentrations below the susceptibility breakpoints, in contrast to no more than 15% for levofloxacin, grepafloxacin, and sparfloxacin. Of the isolates that were multidrug resistant (7.4%), >98% remained susceptible to moxifloxacin. The modal MIC and MIC90 forM. catarrhalis (both 0.06 μg/ml) and forH. influenzae (both 0.03 μg/ml) were independent of β-lactamase production. These data demonstrate the in vitro activity of moxifloxacin and establish a baseline for future studies.